Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5499193 | 1.00 | HMGCR (0.39) | HMGCR | |
| SCHEMBL9490916 | 0.89 | — | — | |
| SCHEMBL9490911 | 0.89 | — | — | |
| SCHEMBL10361224 | 0.88 | — | — | |
| SCHEMBL8160496 | 0.88 | — | — | |
| SCHEMBL10361225 | 0.88 | — | — | |
| SCHEMBL8160494 | 0.88 | — | — | |
| SCHEMBL9493665 | 0.88 | — | — | |
| SCHEMBL10830665 | 0.88 | HMGCR (0.35) | HMGCR | |
| SCHEMBL10830664 | 0.88 | HMGCR (0.35) | HMGCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4567289-A | ANTICHOLESTEROL ANTILIPEMIC | MERCK & CO., INC. (US) | 1986-01-28 | — | — | US | claimed |
| US-7232915-B2 | Process for the synthesis of 1,3-diols | WARNER-LAMBERT COMPANY (US) | 2007-06-19 | — | — | US | disclosed |
| EP-1054860-B1 | PROCESS FOR THE SYNTHESIS OF 1,3-DIOLS | PFIZER IRELAND PHARMACEUTICALS (IE) | 2007-04-25 | — | — | EP | disclosed |
| US-6962994-B2 | Process for the synthesis of 1,3-diols | WARNER-LAMBERT COMPANY, LLC (US) | 2005-11-08 | — | — | US | disclosed |
| US-20050197500-A1 | Process for the synthesis of 1,3-diols | BOSCH ROBERT L (US) | 2005-09-08 | — | — | US | disclosed |
| US-20040006231-A1 | Process for the synthesis of 1,3-diols | BOSCH ROBERT LEE (US) | 2004-01-08 | — | — | US | disclosed |
| US-6596879-B2 | Beta hydroxy ketone treated with trialkylborane or dialkylalkoxyborane followed by recovery and reuse of alkylborane | WARNER-LAMBERT COMPANY | 2003-07-22 | — | — | US | disclosed |
| US-20020161021-A1 | Process for the synthesis of 1,3-diols | BOSCH ROBERT LEE (US) | 2002-10-31 | — | — | US | disclosed |
| US-6433213-B1 | REDUCTION USING BORON COMPOUND | WARNER-LAMBERT COMPANY | 2002-08-13 | — | — | US | disclosed |
| EP-0259087-B1 | PRODRUGS OF ANTIHYPERCHOLESTEROLEMIC COMPOUNDS | MERCK & CO. INC. (US) | 1993-04-07 | — | — | EP | disclosed |
| US-4943588-A | ENZYME INHIBITORS | MERCK & CO., INC. (US) | 1990-07-24 | — | — | US | disclosed |
| US-4837205-A | 1,3-DIOXANE DERIVATIVES | MERCK & CO., INC. (US) | 1989-06-06 | — | — | US | disclosed |
| US-4567289-A | ANTICHOLESTEROL ANTILIPEMIC | MERCK & CO., INC. (US) | 1986-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197500-A1 | Process for the synthesis of 1,3-diols | HSD17B7, HSD11B1, BCKDK | HMGCR 160/4885 |
| US-20020161021-A1 | Process for the synthesis of 1,3-diols | HSD17B7, HSD11B1, BCKDK | HMGCR 160/4885 |
| US-20040006231-A1 | Process for the synthesis of 1,3-diols | HSD17B7, HSD11B1, BCKDK | HMGCR 160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.